Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Extension Study of Levoketoconazole in Endogenous Cushing's Syndrome
2017-004647-20Phase 3Completed
- Sponsor
- Strongbridge Biopharma
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of levoketoconazole in Cushing's syndrome, sponsored by Strongbridge Biopharma. Primary endpoints: Long-term safety of levoketoconazole and Durability of efficacy of levoketoconazole. Started Sep 2018; status: completed.
02
Drugs
levoketoconazole
03
Conditions
Cushing's syndrome
Beyond the preview
Go deeper on 2017-004647-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004647-20.